The firm expects to save more than $35 million in annualized costs through the restructuring. CEO Anne Wojcicki told ...

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

The genetic testing company 23andMe hasn't been doing so hot lately, watching its share price plummet more than 70% this year ...

Home genetics company 23andMe continues to struggle as demand for casual gene tracing declines. On Monday, the company announced that it has decided on a restructuring ...

In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was “taking these difficult but necessary ...

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0616 GMT – Mega Lifesciences is facing pressure from a ...

In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was "taking these difficult but necessary ...

Despite a revenue decline, 23andMe Holding Co (ME) focuses on cost-saving measures and recurring revenue growth to enhance financial stability.

CEO Anne Wojcicki, who holds roughly half of the voting power, is attempting to take the company private. In September, seven ...